Search company, investor...

Founded Year




Total Raised


Market Cap




About Oxurion

Oxurion (Euronext Brussels: OXUR) operates a biopharmaceutical company that focuses on the development of therapeutics for conditions related to the vascular system. It offers drug candidates for cardiovascular diseases, visual disorders, and cancer. The company was founded in 1998 and is based in Leuven, Belgium.

Headquarters Location

Gaston Geenslaan 1

Leuven, B-3001,





Oxurion Patents

Oxurion has filed 24 patents.

The 3 most popular patent topics include:

  • diseases of the eye and adnexa
  • angiology
  • clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Diseases of the eye and adnexa, G protein coupled receptors, Transcription factors, Integrins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Diseases of the eye and adnexa, G protein coupled receptors, Transcription factors, Integrins



Latest Oxurion News

Oxurion Announces New Strategic Orientation to De-risk and Diversify

Jan 22, 2024

Oxurion Announces New Strategic Orientation to De-risk and Diversify January 22, 2024 at 04:03 pm EST Share Leuven, BELGIUM, 22 January 2024 9:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further diversify its activities by actively considering M&A opportunities, specifically in the healthcare sector. Pascal Ghoson, CEO of Oxurion, states, “Oxurion today lays out its new corporate strategy, which is designed to further diversify and de-risk its ongoing activities. Starting March 2024, with a dedicated team of ten, we will proactively seek M&A opportunities, with a focus on healthcare companies to leverage the team’s expertise. This approach is not just about growth; it’s about enhancing our market presence with a robust business plan.” Enhanced Funding Strategy Atlas is currently the main funding partner of Oxurion, which has invested in the company by means of convertible bonds. “In the future we aim to use equity and debt funding to address our M&A targets. We are considering M&A transactions in the healthcare industry, where we can create the most added value with the current team. Our M&A pursuits will primarily target the healthcare industry in France and the Benelux region. We are interested in revenue-generating, mature businesses that promise lower risk and high potential,” Pascal Ghoson adds. Commitment to Euronext Listing and Shareholder Engagement The company is firmly committed to maintaining its listing on Euronext. "We have no intention of delisting from Euronext. Our evolving strategy is likely to attract significant investor interest. We are reaching out to our existing and new shareholders to become part of this new exciting story and are looking for long-term investors. Our prime objective is to identify the targets, either on a case- by-case basis, or as a combination of smaller targets to create synergies and added value for our shareholders. Valuations have come down compared to a couple of years ago and this provides us with more acquisition opportunities.” About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is headquartered in Leuven, Belgium. More information is available at Important information about forward-looking statements Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. For further information please contact: Oxurion NV Oxurion NV is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide. Oxurion NV is aiming to build the leading global franchise in the treatment of DME, based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all DME patients. Sector

Oxurion Frequently Asked Questions (FAQ)

  • When was Oxurion founded?

    Oxurion was founded in 1998.

  • Where is Oxurion's headquarters?

    Oxurion's headquarters is located at Gaston Geenslaan 1, Leuven.

  • What is Oxurion's latest funding round?

    Oxurion's latest funding round is PIPE.

  • How much did Oxurion raise?

    Oxurion raised a total of $35M.

  • Who are the investors of Oxurion?

    Investors of Oxurion include Noshaq, Banque CPH, Negma Group, KU Leuven and Gimv.

  • Who are Oxurion's competitors?

    Competitors of Oxurion include Aphios, Oligomerix, Sierra Oncology, Dare Bioscience, Array Biopharma and 7 more.


Compare Oxurion to Competitors


AM-Pharma is a biopharmaceutical company that focuses on developing treatments for severe medical conditions. The company's main offerings include the development of a proprietary compound for the treatment of cardiac surgery-associated renal damage and hypophosphatasia, a rare disease. The company primarily serves the healthcare industry. It was founded in 2001 and is based in Utrecht, Netherlands.


BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Oligomerix Logo

Oligomerix is a biotechnology company that focuses on the development of disease-modifying therapeutics for neurodegenerative diseases, specifically those characterized by aberrant tau protein. The company's main offerings include small molecule inhibitors that target the tau aggregation cascade and its progression, aiming to treat conditions ranging from rare tauopathies to Alzheimer's disease. The company primarily serves the healthcare sector, particularly in the area of neurodegenerative diseases. It was founded in 2006 and is based in West Harrison, New York.

Cerecin Logo

Cerecin is a healthcare company that focuses on brain health. The company develops a range of products including pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, all aimed at addressing conditions ranging from memory impairment to severe neurological diseases. Cerecin was formerly known as Accera. It was founded in 2001 and is based in Singapore, Singapore.


TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Aphios Logo

Aphios is a clinical stage biotechnology company. It develops technology platfroms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, the company develops therapeutics to prevent disease, maintain health, and treat chronic diseases, including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19. The company was founded in 2018 and is based in Woburn, Massachusetts.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.